DHTKD1 and prostate cancer: However, improvements in future therapies for prostate cancer will likely include multimodal strategies and we suggest that to optimise efficacy, the intrinsic sensitizing properties of E1A and deletion of small protein-binding domains such as the p400/p21-binding region, should be investigated in combination with the highly potent and selective AdΔCR2 mutants.